Edition:
India

AzurRx BioPharma Inc (AZRX.OQ)

AZRX.OQ on NASDAQ Stock Exchange Capital Market

3.42USD
23 Jan 2018
Change (% chg)

$-0.06 (-1.72%)
Prev Close
$3.48
Open
$3.51
Day's High
$3.54
Day's Low
$3.40
Volume
12,200
Avg. Vol
13,020
52-wk High
$5.25
52-wk Low
$2.40

Select another date:

Thu, Jan 18 2018

BRIEF-AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD

* AZURRX BIOPHARMA ANNOUNCES RECEIPT OF REQUIRED APPROVALS TO ADD FRENCH CLINICAL SITE FOR ITS PHASE IIA STUDY OF MS1819-SD FOR EXOCRINE PANCREATIC INSUFFICIENCY

BRIEF-AzurRx Biopharma receives $2 mln in proceeds from exercise of warrants

* AZURRX BIOPHARMA RECEIVES $2 MILLION IN PROCEEDS FROM EXERCISE OF WARRANTS

BRIEF-AzurRx Biopharma files for mixed shelf offering of up to $10 mln

* AzurRx Biopharma Inc files for mixed shelf offering of up to $10 million - SEC filing‍​ Source text: [http://bit.ly/2z4AEuv] Further company coverage:

BRIEF-Azurrx Biopharma, Mayoly Spindler announce IMPD submission

* Azurrx Biopharma and Mayoly Spindler announce MS1819-SD investigational medicinal product dossier (IMPD) submission

BRIEF-AzurRx BioPharma files for stock shelf of upto $10 mln

* Azurrx biopharma inc files for stock shelf of upto $10 million - sec filing‍​‍​ Source text for Eikon: (http://bit.ly/2hChpOb) Further company coverage:

BRIEF-AzurRx Biopharma announces positive MS1819-SD Phase II data in exocrine pancreatic insufficiency

* AzurRx Biopharma and Mayoly-Spindler announce positive MS1819-SD phase II data in exocrine pancreatic insufficiency (epi)

BRIEF-Azurrx announces appointment of Chief Financial Officer

* Azurrx announces appointment of Maged Shenouda as Chief Financial Officer Source text for Eikon: Further company coverage:

BRIEF-Azurrx reaches 6th patient enrollment of midstage trial for pancreas drug

* Azurrx reaches 6th patient enrollment of Phase IIA trial of MS1819 for treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis

BRIEF-Azurrx Biopharma enters into sublicense agreement with Transchem

* Azurrx Biopharma Inc - ‍on August 7, 2017, Azurrx Biopharma, Inc entered into a sublicense agreement with Transchem, Inc. - sec filing​

Select another date: